Summary
This narrative review examines the epidemiological, preclinical, and clinical evidence linking type 2 diabetes to Parkinson's disease aetiology, with particular emphasis on insulin resistance and chronic inflammation as shared pathogenic mechanisms. The author synthesises recent findings on how T2D may initiate and exacerbate PD brain pathology and discusses the rationale for alternative pharmacological approaches to PD management.
UK applicability
Given the high prevalence of both type 2 diabetes and Parkinson's disease in the UK, understanding their mechanistic overlap has implications for clinical assessment and management protocols in UK primary and secondary care. The review's discussion of alternative pharmacological interventions may inform UK therapeutic guidelines and research commissioning priorities.
Key measures
Evidence on insulin resistance, chronic inflammation, and their contribution to overlapping aetiologies of T2D and PD; brain pathology markers
Outcomes reported
This narrative review synthesises recent evidence on how type 2 diabetes contributes to the initiation and progression of Parkinson's disease brain pathology. The paper also discusses alternative pharmacological interventions for Parkinson's disease treatment.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.